Patient characteristics
. | No. patients or units (range) . |
|---|---|
| Total patients | 110 |
| Median age, y | 43.5 (19-62) |
| Diagnosis | |
| Acute leukemia | 55 |
| CR1 | 17 |
| CR2/3 | 15 |
| Relapse | 23 |
| CML | 20 |
| CP* | 9 |
| AP | 4 |
| BP | 7 |
| MDS | 16 |
| RA | 10 |
| Other | 6 |
| NHL | 12 |
| CR | 2 |
| Persistent disease | 10 |
| Other† | 7 |
| Diagnostic risk group‡ | |
| Good§ | 26 |
| Poor | 84 |
| Follow-up for living patients, d | 850 (354-1588) |
. | No. patients or units (range) . |
|---|---|
| Total patients | 110 |
| Median age, y | 43.5 (19-62) |
| Diagnosis | |
| Acute leukemia | 55 |
| CR1 | 17 |
| CR2/3 | 15 |
| Relapse | 23 |
| CML | 20 |
| CP* | 9 |
| AP | 4 |
| BP | 7 |
| MDS | 16 |
| RA | 10 |
| Other | 6 |
| NHL | 12 |
| CR | 2 |
| Persistent disease | 10 |
| Other† | 7 |
| Diagnostic risk group‡ | |
| Good§ | 26 |
| Poor | 84 |
| Follow-up for living patients, d | 850 (354-1588) |
RA indicates refractory anemia.
Includes 6 and 3 patients who underwent transplantation less than or more than 2 years from diagnosis, respectively.
SAA (3), CLL (2), MF (2).
Good indicates acute leukemia in CR1 or CML in CP. Poor indicates acute leukemia in relapse or CR2 or beyond, CML in accelerated phase (AP) or blast phase (BP), MDS, NHL, CLL, SAA, or MF.
Includes 18 patients with good risk diagnoses having high-risk characteristics as defined in “Patients, materials, and methods” (adverse cytogenetic abnormalities [14], high peripheral blast count at diagnosis [2], late CP [2]).